Definium Therapeutics

DFTX · Nasdaq · United States

Share price · DFTX

$29.12-17.06 (-36.94%) 3M

close as of 2026-11-18 · 24h delayed · vol 1.9M (1.1x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when DFTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 6 Nov 2026+9.6%

    Nothing announced by DFTX that day or the session before.

  2. 2 Nov 2026-10.6%

    Nothing announced by DFTX that day or the session before.

  3. 24 Jun 2026+16.4%
  4. 22 Jun 2026+49.8%
  5. 15 Jun 2026-4.0%
  6. 21 May 2026+8.5%
  7. 8 May 2026-5.0%
  8. 27 Apr 2026-6.7%

    Nothing announced by DFTX that day or the session before.

  9. 1 Apr 2026+9.0%
  10. 20 Jan 2026+11.5%

Share of unusual movement by asset

For each asset, the share of DFTX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Lysergide tartrate (LSD) (DT120)
events and moves
1422%
Other company news (earnings, financing, releases naming no asset)—26%
Sessions with no dated event—52%

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
3Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
5-HT2A receptorSmall molecule
Major Depressive DisorderAttention Deficit Hyperactivity DisorderGeneralized Anxiety Disorder

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
Lysergide tartrate (LSD) · DT120Phase 3Major Depressive Disorder
Est. primary completion 2027-09 · NCT07592689 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 September 2026Topline resultDT120 (lysergide tartrate ODT)Phase 3 Panorama (NCT06809595) met its primary endpoint in GAD
Definium Therapeutics · Source ↗
12 August 2026Topline resultDT120 (lysergide tartrate ODT)Phase 3 Voyage (NCT06741228) reported positive topline results in GAD
Definium Therapeutics · Source ↗
22 June 2026Topline resultLysergide tartrate (LSD)Emerge Phase 3 meets primary endpoint
Definium Therapeutics · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$46M$241M+ $806M short-term inv.$51M-$53M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$49M$655M+ $429M short-term inv.$159M-$53M operating cash flowreport ↗
2026-Q1—$41M$263M+ $111M short-term inv.$77M-$43M operating cash flowreport ↗
2025-Q3—$31M$20M+ $189M short-term inv.$67M-$30M operating cash flowreport ↗
2025-Q2—$30M$33M+ $150M short-term inv.$43M-$30M operating cash flowreport ↗
2025-Q1—$23M$83M+ $130M short-term inv.$23M-$29M operating cash flowreport ↗
2024-Q3—$17M$295M$14M-$17M operating cash flowreport ↗
2024-Q2—$15M$243M$5.8M-$20M operating cash flowreport ↗
2024-Q1—$12M$252M$54M-$17M operating cash flowreport ↗
2023-Q3—$13M$118M$18M-$17M operating cash flowreport ↗
2023-Q2—$15M$117M$29M-$14M operating cash flowreport ↗
2023-Q1—$13M$129M$25M-$13M operating cash flowreport ↗
2022-Q3—$7.8M$155M$16M-$9.3M operating cash flowreport ↗
2022-Q2—$9.3M$106M$17M-$15M operating cash flowreport ↗
2022-Q1—$10M$120M$18M-$13M operating cash flowreport ↗
2021-Q3—$9.0M—$17M-$17M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$118M$258M+ $154M short-term inv.$46M-$132M operating cash flowreport ↗

Definium Therapeutics reported full-year 2025 results with revenue not disclosed. R&D expense was $117.67M, up 80.2% YoY, and the company posted a net loss of $183.79M, with a quarterly net burn of $183.79M. Cash and equivalents stood at $257.84M, while total cash, cash equivalents, and investments were $411.6M as of December 31, 2025, compared to $273.7M in the prior year.

Management expects the $411.6M cash position to fund operations into 2028. Clinically, the Phase 3 MDD trial Emerge is fully enrolled with topline data anticipated in late 2Q 2026, the Phase 3 GAD trial Voyage is approximately 80% enrolled with topline data expected in early 3Q 2026, and the Phase 3 GAD trial Panorama remains on track for a 2H 2026 readout. Additional highlights include the completed ~$259M equity financing, publication of Phase 2b GAD results in JAMA, initiation of a Phase 2a study for DT402 in autism spectrum disorder, and a planned Investor and Analyst Day on April 22, 2026.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$65M$274M+ $0 short-term inv.$27M-$79M operating cash flowreport ↗
2023-FY—$52M$100M$24M-$64M operating cash flowreport ↗
2022-FY—$36M$142M$14M-$50M operating cash flowreport ↗
2021-FY—$35M$134M$23M-$46M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 17 sales ($7.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-25Roberts Brandi · Chief Financial OfficerOpen-market sale3,377$36.57$123KForm 4
2026-09-25Sullivan Mark · Chief Legal OfficerOpen-market sale14,051$36.57$514KForm 4
2026-09-25Wiley Matthew T. · Chief Commercial OfficerOpen-market sale3,097$36.57$113KForm 4
2026-09-25Barrow Robert · director, Chief Executive OfficerOpen-market sale31,550$36.57$1.2MForm 4
2026-09-25Karlin Daniel · director, Chief Medical OfficerOpen-market sale10,853$36.57$397KForm 4
2026-09-18Vallone Carol A · directorOption exercise1,086$35.52$39KForm 4
2026-09-18Krebs Andreas · directorOption exercise1,629$35.52$58KForm 4
2026-09-18Vallone Carol A · directorOption exercise (derivative)1,086——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 245 reporting institutions held 78.4M shares ($1.5B, 71.8% of shares outstanding).

#InstitutionSharesValue
1BlackRock, Inc.8,480,230$160.3M
2Driehaus Capital Management LLC5,911,889$111.7M
3Avoro Capital Advisors LLC5,000,000$94.5M
4JANUS HENDERSON GROUP PLC3,556,041$67.2M
5Deep Track Capital, LP3,000,000$56.7M
6GEODE CAPITAL MANAGEMENT, LLC2,495,399$47.2M
7STATE STREET CORP2,471,873$46.7M
8Octagon Capital Advisors LP2,440,000$46.1M
9Commodore Capital LP2,000,000$37.8M
10FMR LLC1,809,610$34.2M
11Trails Edge Capital Partners, LP1,738,110$32.9M
12GOLDMAN SACHS GROUP INC1,675,411$31.7M
13ArrowMark Colorado Holdings LLC1,594,717$30.1M
14CITADEL ADVISORS LLC1,333,442$25.2M
15WELLINGTON MANAGEMENT GROUP LLP1,304,749$24.7M